Cited by 456Global Cancer Incidence and ScreeningCancer survivorship and careEconomic and Financial Impacts of Cancer

Cancer survivors: a booming population

Open access
Parry, Carla, Kent, Erin E., Mariotto, Angela B., Alfano, Catherine M., Rowland, Julia H.·2011·Cancer Epidemiology, Biomarkers & Prevention

Abstract

Background: In this first article of what is planned to be an annual series, we examine the history of cancer prevalence reporting and the role that these annual figures play in guiding the direction of cancer control research, and specifically the science of cancer survivorship. For this inaugural year, we focus on the confluence of the growing number of survivors and population aging, and the impact these combined trends will have on cancer survivorship in the future. Methods: State or metro area-level cancer incidence and prevalence data were collected from 9 registries via the Surveillance, Epidemiology, and End Results Program. The complete prevalence method was used to estimate prevalence for 2008 and the Prevalence, Incidence Approach Model method was used to project prevalence data through 2020, assuming flat cancer incidence and survival trends but dynamic U.S. population projections. Results: As of January 2008, the number of cancer survivors is estimated at 11.9 million. Approximately 60% of cancer survivors are age 65 or older, and by the year 2020, it is estimated that 63% of cancer survivors will be age 65 or older. Conclusions: Improved survival and population aging converge to generate a booming population of older adult cancer survivors, many of whom have multiple complex health conditions and unique survivorship needs. This demographic shift has important implications for future health care needs and costs of the U.S. population. Impact: The findings provide information critical for guiding cancer prevention and control research and service provision. Cancer Epidemiol Biomarkers Prev; 20(10); 1996–2005. ©2011 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-11-0729

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [6]Mariotto A Gigli A Capocaccia R Tavilla A Clegg LX Depry M Ries LAG Eisner MP Kosary CL Complete and Limited Duration Cancer Prevalence Estimates SEER Cancer Statistics Review, 1973–1999 2002 Bethesda, MD National Cancer Institute

Cited by

Sorted by citations

Authors
Parry, C., Kent, E. E., Mariotto, A. B., Alfano, C. M., & Rowland, J. H.
Affiliations
National Institutes of Health (US)
Corresponding author
Rowland, Julia H.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2011-10-01
Volume
20
Issue
10
Pages
1996-2005
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W2096597021
Cited by
456
References
42
Citations by year
2026: 8 · 2025: 19 · 2024: 24 · 2023: 27 · 2022: 33 · 2021: 32 · 2020: 30 · 2019: 30 · 2018: 43 · 2017: 34 · 2016: 37 · 2015: 29 · 2014: 47 · 2013: 38 · 2012: 20
FWCI
17.34
Type
journal article
Language
en
Open access
Locations
  • Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (Z99 CA999999)
  • National Cancer Institute (Y99 CA999999)
Topics
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
Keywords
cancer survivors, cancer prevalence, population aging, older adults, cancer incidence, cancer survivorship, prevalence projections, SEER database, cancer control, health care costs
MeSH terms
Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Population Surveillance, Time Factors, Incidence, Prevalence, Survival Rate, Survivors, SEER Program, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review